Jing Feng, Ti Wen, Zhi Li, Liang Feng, Lu Zhou, Zichang Yang, Lu Xu, Sha Shi, Kezuo Hou, Jiming Shen, Xu Han, Yuee Teng
Hormone receptor-positive breast cancer accounts for around 75% of breast cancers. The estrogen receptor pathway promotes tumor progression and endocrine resistance. Recently, the cross-talk between the ER signaling pathway and cell cycle regulation has been identified. It is necessary to determine the underlying molecular mechanisms involved in the ER signaling pathway and find new target genes for prognosis and drug resistance in ER+ breast cancer. In this study, lncRNA MAFG-AS1 was shown to be up-regulated and associated with poor prognosis in ER+ breast cancer...
October 24, 2020: Aging
Danielle D Durham, Megan C Roberts, Carly P Khan, Linn A Abraham, Robert A Smith, Karla Kerlikowske, Diana L Miglioretti
PURPOSE: Women with a first-degree family history of breast cancer (FHBC) are sometimes advised to initiate screening mammography when they are 10 years younger than the age at which their youngest relative was diagnosed, despite a lack of unambiguous evidence that this is an effective strategy. It is unknown how often this results in women initiating screening earlier (< 40 years) than screening guidelines recommend for average-risk women. METHODS: We examined screening initiation age by FHBC and age at diagnosis of the youngest relative using data collected by the Breast Cancer Surveillance Consortium on 74,838 first screening mammograms performed between 1996 and 2016...
October 24, 2020: Cancer Causes & Control: CCC
I K Vorotnikov, I V Vysotskaya, D A Denchik, V P Letyagin, M M Davydov, V Yu Kirsanov, E A Kim, V S Buseva
Prognosis for some histological variants of a rare breast disease, phyllodes tumors, is evaluated. The prognostic potential of some molecular biological factors significantly correlating with breast cancer prognosis is evaluated on a unique clinical material (244 cases with benign, intermediate, and malignant phyllodes tumors). The development of benign phyllodes tumor relapse directly correlated with the number of G0/1-phase cells and inversely correlated with the number of cells in the G2+M and S phases. The level of steroid hormone receptors in phyllodes tumors cannot serve as a prognostic marker predicting the disease course...
October 24, 2020: Bulletin of Experimental Biology and Medicine
Yuan Yuan, Jin Sun Lee, Susan E Yost, Sierra Min Li, Paul H Frankel, Christopher Ruel, Daniel Schmolze, Kim Robinson, Aileen Tang, Norma Martinez, Daphne Stewart, James Waisman, Laura Kruper, Veronica Jones, Andrea Menicucci, Sahra Uygun, Erin Yoder, Bastiaan van der Baan, John H Yim, Christina Yeon, George Somlo, Joanne Mortimer
BACKGROUND: In this phase II clinical trial, we evaluated the efficacy of the non-anthracycline combination of carboplatin and nab-paclitaxel in early stage triple negative breast cancer (TNBC). PATIENTS AND METHODS: Patients with newly diagnosed stage II-III TNBC (N=69) were treated with neoadjuvant carboplatin (AUC 6) every 28 days x 4 plus nab-paclitaxel (100 mg/m2 ) weekly for 16 weeks. Pathological complete response (pCR) and residual cancer burden (RCB) were analyzed with germline mutation status, tumor infiltrating lymphocytes (TILs), TNBC molecular subtype, and GeparSixto immune signature (GSIS)...
October 24, 2020: Oncologist
Nuthasuda Srijakotre, Heng-Jia Liu, Max Nobis, Joey Man, Hon Yan Kelvin Yip, Antonella Papa, Helen E Abud, Kurt I Anderson, Heidi C E Welch, Tony Tiganis, Paul Timpson, Catriona A McLean, Lisa M Ooms, Christina A Mitchell
The Rac-GEF, P-Rex1, activates Rac1 signaling downstream of G protein-coupled receptors and PI3K. Increased P-Rex1 expression promotes melanoma progression; however, its role in breast cancer is complex, with differing reports of the effect of its expression on disease outcome. To address this we analyzed human databases, undertook gene array expression analysis, and generated unique murine models of P-Rex1 gain or loss of function. Analysis of PREX1 mRNA expression in breast cancer cDNA arrays and a METABRIC cohort revealed that higher PREX1 mRNA in ER+ve /luminal tumors was associated with poor outcome in luminal B cancers...
October 23, 2020: Proceedings of the National Academy of Sciences of the United States of America
Dawid Sigorski, Paweł Sobczuk, Małgorzata Osmola, Kamil Kuć, Anna Walerzak, Michal Wilk, Tomasz Ciszewski, Sylwia Kopeć, Karolina Hryń, Piotr Rutkowski, Rafał Stec, Cezary Szczylik, Lubomir Bodnar
BACKGROUND: Life-threatening diseases have a negative impact on emotional well-being and psychosocial functioning. This study aimed to assess the relationship between the level of anxiety caused by a neoplasm and the threat of coronavirus infection among patients with cancer actively treated with systemic therapy during the COVID-19 pandemic. Additionally, we searched for clinical factors associated with a higher level of anxiety. METHODS: In this multicentre, prospective, non-interventional study conducted in Poland, we enrolled 306 actively treated patients with cancer and collected their clinical data, including age, gender, cancer type and treatment intention...
October 2020: ESMO Open
Sarah J Kurley, Verena Tischler, Brian Bierie, Sergey V Novitskiy, Aurelia Noske, Zsuzsanna Varga, Ursina Zürrer-Härdi, Simone Brandt, Robert H Carnahan, Rebecca S Cook, William J Muller, Ann Richmond, Albert B Reynolds
We have examined the effects of targeted p120 KO in a PyMT mouse model of invasive ductal (mammary) cancer (IDC). Mosaic p120 ablation had little effect on primary tumor growth but caused significant pro-metastatic alterations in the tumor microenvironment leading ultimately to a marked increase in the number and size of pulmonary metastases. Surprisingly, although early effects of p120-ablation included decreased cell-cell adhesion and increased invasiveness, cells lacking p120 were almost entirely unable to colonized distant metastatic sites in vivo...
October 23, 2020: Journal of Cell Science
Halei C Benefield, Gary R Zirpoli, Emma H Allott, Yue Shan, Amber N Hurson, Angela R Omilian, Thaer Khoury, Chi-Chen Hong, Andrew F Olshan, Traci N Bethea, Elisa V Bandera, Julie R Palmer, Christine B Ambrosone, Melissa A Troester
BACKGROUND: Evidence suggests etiologic heterogeneity among breast cancer subtypes. Previous studies with six-marker immunohistochemical classification of intrinsic subtypes included small numbers of black women. METHODS: Using centralized laboratory results for estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 (HER2), proliferation marker Ki-67, epidermal growth factor receptor (EGFR), and cytokeratin (CK)5/6, we estimated case-only and case-control odds ratios (ORs) for established breast cancer risk factors among cases (n=2,354) and controls (n =2,932) in the African American Breast Cancer Epidemiology and Risk (AMBER) consortium...
October 23, 2020: Cancer Epidemiology, Biomarkers & Prevention
Ann D Thor, Reema S Wahdan-Alaswad, Susan M Edgerton, Hiba Salem, Hyunmin Kim, Aik-Choon Tan, Jessica Finlay-Schultz, Elizabeth Wellberg, Carol A Sartorius, Britta M Jacobsen, Bryan R Haugen, Bolin Liu
PURPOSE: Thyroid disease is a frequent comorbidity in women with breast cancer (BC), and many require thyroid hormone(TH) replacement therapy(THRT). We postulated that THRT has a deleterious clinical effect mechanistically through hormonal interactions, nuclear receptor cross-talk and upregulation of high-risk BC genes. EXPERIMENTAL DESIGN: Observational studies of lymph node-negative (LN-) BC patients (n= 820 and n=160) were performed to test interactions between THRT and clinical, histologic, outcome and treatment variables...
October 23, 2020: Clinical Cancer Research
Julian O Kim, Daniel J Schaid, Celine M Vachon, Andrew Cooke, Fergus J Couch, Christina A Kim, Jason P Sinnwell, Linda Hasadsri, Daniela L Stan, Benjamin A Goldenberg, Lonzetta Neal, Debjani Grenier, Amy C Degnim, Lori A Thicke, Sandhya Pruthi
Endocrine therapy (ET) is underutilized to reduce breast cancer (BC) incidence among women at increased risk. Polygenic risk scores (PRSs) assessing 77 BC genetic susceptibility loci personalizes risk estimates. We examined effect of personalized PRS BC risk prediction on intention to take and ET uptake among women recruited from BC clinics. Eligible participants had a 10-year BC risk >5% by Tyrer-Cuzick model (International Breast Cancer Intervention Study [IBIS]) or >3.0 % 5-year Gail Model risk with no BC history or hereditary BC syndrome...
October 23, 2020: Cancer Prevention Research
Sumit Siddharth, Anmada Nayak, Sarita Das, Deepika Nayak, Jyochanamayi Panda, Michael D Wyatt, Chanakya Nath Kundu
No abstract text is available yet for this article.
October 20, 2020: International Journal of Biochemistry & Cell Biology
Simona Di Lascio, Enrico Tognazzo, Sara Bigiotti, Marta Bonollo, Alberto Costa, Olivia Pagani, Francesco Meani
INTRODUCTION: Risk of breast cancer increases with age and very few data are available in patients older than 89. METHODS: A retrospective analysis on patients aged 89 and older treated between 2008 and 2019 at our certified breast center. The aim was to analyze clinical characteristics, decision-making, treatment, outcomes and open questions regarding this subpopulation for which there is a lack of guidelines. RESULTS: 58 patients included...
October 13, 2020: European Journal of Surgical Oncology
Juan Ruiz, Gerson Maldonado, Elizabeth Ablah, Hayrettin Okut, Jared Reyes, Karson Quinn, Patty L Tenofsky
BACKGROUND: The Society of Surgical Oncology introduced guidance discouraging routine axillary staging in women 70 years or older with invasive, clinically node negative, hormone-receptor positive breast cancer. Due to concerns this could result in patients missing necessary treatment, researchers from the Mayo Clinic developed a rule to distinguish between those at low/high-risk of having positive nodes. The purpose of this study was to validate the Mayo Clinic rule in women of all ages...
October 6, 2020: American Journal of Surgery
Na Hui Kim, Nam Ji Sung, Hyung-Sun Youn, Sin-Aye Park
Gremlin-1 (GREM1), one of the antagonists of bone morphogenetic proteins (BMPs), has recently been reported to be overexpressed in a variety of cancers including breast cancer. GREM1 is involved in tumor promotion, but little is known about its role in the glycolysis of cancer cells. In this study, we investigated the role of GREM1 in glycolysis of breast cancer cells and its underlying molecular mechanisms. We first observed that glucose uptake and lactate production were increased in GREM1-overexpressing breast cancer cells...
October 20, 2020: Biochemical and Biophysical Research Communications
Amelie de Gregorio, Lothar Häberle, Peter A Fasching, Volkmar Müller, Iris Schrader, Ralf Lorenz, Helmut Forstbauer, Thomas W P Friedl, Emanuel Bauer, Nikolaus de Gregorio, Miriam Deniz, Visnja Fink, Inga Bekes, Ulrich Andergassen, Andreas Schneeweiss, Hans Tesch, Sven Mahner, Sara Y Brucker, Jens-Uwe Blohmer, Tanja N Fehm, Georg Heinrich, Krisztian Lato, Matthias W Beckmann, Brigitte Rack, Wolfgang Janni
BACKGROUND: When chemotherapy is indicated in patients with early breast cancer, regimens that contain anthracyclines and taxanes are established standard treatments. Gemcitabine has shown promising effects on the response and prognosis in patients with metastatic breast cancer. The SUCCESS-A trial (NCT02181101) examined the addition of gemcitabine to a standard chemotherapy regimen in high-risk early breast cancer patients. METHODS: A total of 3754 patients with at least one of the following characteristics were randomly assigned to one of the two treatment arms: nodal positivity, tumor grade 3, age ≤ 35 years, tumor larger than 2 cm, or negative hormone receptor status...
October 23, 2020: Breast Cancer Research: BCR
Vincenzo Quagliariello, Michelino De Laurentiis, Stefania Cocco, Giuseppina Rea, Annamaria Bonelli, Antonietta Caronna, Maria Cristina Lombari, Gabriele Conforti, Massimiliano Berretta, Gerardo Botti, Nicola Maurea
Hyperglycemia, obesity and metabolic syndrome are negative prognostic factors in breast cancer patients. Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, achieving unprecedented efficacy in multiple malignancies. However, ICIs are associated with immune-related adverse events involving cardiotoxicity. We aimed to study if hyperglycemia could affect ipilimumab-induced anticancer efficacy and enhance its cardiotoxicity. Human cardiomyocytes and estrogen-responsive and triple-negative breast cancer cells (MCF-7 and MDA-MB-231 cell lines) were exposed to ipilimumab under high glucose (25 mM); low glucose (5...
October 21, 2020: International Journal of Molecular Sciences
Alma Rosa Oaxaca-Camacho, Oscar René Ochoa-Mojica, Adriana Aguilar-Lemarroy, Luis F Jave-Suárez, José Francisco Muñoz-Valle, Eduardo Padilla-Camberos, Juan Antonio Núñez-Hernández, Sara E Herrera-Rodríguez, Moisés Martínez-Velázquez, Ahtziri Socorro Carranza-Aranda, José Alfonso Cruz-Ramos, Abel Gutiérrez-Ortega, Rodolfo Hernández-Gutiérrez
Background: Several studies have shown that patients with cancer have antibodies in serum that react with cellular autoantigens, known as Tumor-Associated Antigens (TAA). The present work aimed to determine whether a mini-array comprising four recombinant TAA increases the detection of specific serum antibodies for the diagnosis of early-stage breast cancer. Methods: The mini-array included Alpha 1-AntiTrypsin (A1AT), TriosePhosphate Isomerase 1 (TPI1), Peptidyl-Prolyl cis-trans Isomerase A (PPIA), and PeroxiReDoXin 2 (PRDX2) full-length recombinant proteins...
October 21, 2020: Biosensors
Rui Guo, Yu Chen, Heather Borgard, Mayumi Jijiwa, Masaki Nasu, Min He, Youping Deng
Lipids are essential components of cell structure and play important roles in signal transduction between cells and body metabolism. With the continuous development and innovation of lipidomics technology, many studies have shown that the relationship between lipids and cancer is steadily increasing, involving cancer occurrence, proliferation, migration, and apoptosis. Breast cancer has seriously affected the safety and quality of life of human beings worldwide and has become a significant public health problem in modern society, with an especially high incidence among women...
October 21, 2020: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
Yael Keren, Racheli Magnezi, Moshe Carmon, Yona Amitai
Risk and protective factors for breast cancer (BC) include lifestyle, diet, reproduction, and others. Increased risk for colon cancer was linked with low water intake. The link between water consumption and BC was scarcely studied. We investigated the association between water and fluid consumption and the occurrence of BC in a retrospective case-control study in the Shaare Zedek Medical Center, Jerusalem, in 206 women aged 25-65 years (106 with newly diagnosed BC, and 100 controls). A food frequency questionnaire (FFQ), consumption of water, foods, and beverages, lifestyle, and other risk and protective factors were recorded...
October 21, 2020: International Journal of Environmental Research and Public Health
Domenico Iacopetta, Rosamaria Lappano, Annaluisa Mariconda, Jessica Ceramella, Maria Stefania Sinicropi, Carmela Saturnino, Marianna Talia, Francesca Cirillo, Fabio Martinelli, Francesco Puoci, Camillo Rosano, Pasquale Longo, Marcello Maggiolini
Breast cancer represents the most frequently diagnosed malignancy in women worldwide. Various therapeutics are currently used in order to halt the progression of breast tumor, even though certain side effects may limit the beneficial effects. In recent years, many efforts have been addressed to the usefulness of natural compounds as anticancer agents due to their low toxicity. Resveratrol, a stilbene found in grapes, berries, peanuts and soybeans, has raised a notable interest for its antioxidant, anti-inflammatory, and antitumor properties...
October 21, 2020: International Journal of Molecular Sciences
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"